1. ALLA AKTIER
  2. NYHETER
  3. DIGNITANA

Dignitana

Nyheter Dignitana Nyheter alla bolag
Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.

Dignitana AB Publishes Q1 2024 Interim Report

REG

Continued progress with increasing activity and awareness

Financial highlights Q1 2024
  • Net Sales amounted to 21.2 MSEK (21.5), a decrease of 2 percent over the same quarter in 2023.
  • Operating Result amounted to -5.0 MSEK (-3.5).
  • Net Result after financial items amounted to -5.1 MSEK (-3.9).
  • EBITDA for the First Quarter is negative at -1.1 MSEK (0.2).
  • Earnings per share were -0.07 SEK (-0.06).
  • Cash Balance amounted at 2.8 MSEK (11.7).
  • Average Daily Treatment Revenue (ADTR)* was 241 TSEK (242) in the quarter.
Business highlights during the period
  • Dignitana held an Extraordinary General Meeting to resolve on the rights issue and to obtain a bridge loan.
  • Dignitana convened Training Academy bringing distributors to Lund Headquarters.
  • DigniCap Delta received market approval in Japan with Konica Minolta as Dignitana’s Distribution partner.
  • Dignitana signed OncoMedical for distribution in Switzerland and Liechtenstein.
  • Preliminary result of DigniCap Delta study in Uruguay demonstrated very high efficacy compared to previous studies.
  • DigniCap Delta study is underway in Brindisi, Italy.
  • Dignitana nominated for Inaugural Texas Impact Enterprise Awards.
  • Dignitana invited to address MedTech innovation on a panel at SXSW® conference in Texas.
Business highlights after the period
  • Dignitana Rights Issue was fully subscribed at 19.1 MSEK before issue cost.
  • Fredrik Jonsson appointed as CEO beginning 1 May 2024 following resignation of Caterina Lowenadler.
  • Dignitana signed an exclusivity agreement with Konica Minolta as distributor for DigniCap in Japan.
  • Dignitana exhibited at the Oncology Nursing Congress in Washington, DC

Key Figures
DIGNITANA GROUP Q1 2024 Q1 2023 Full year 2023
Net sales, TSEK 21,165 21,489 86,063
Total revenues, TSEK 21,288 21,605 89,025
Net profit after financial items, TSEK -5,056 -3,938 -17,228
Cash and bank balances, TSEK 2,839 11,726 6,027
Earnings per share before and after dilution, SEK -0.07 -0.06 -0.25
Average Daily Treatment revenue*, TSEK 241 242 239

*ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

All financial reports are available at www.dignitana.com/investor-relations/financial-reports/

This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-05-2024 08:00 CET.

Datum 2024-05-23, kl 08:00
Källa Cision
Bifogade filer
240523 Q1-24 Dignitana